Ametropia and presbyopia successfully treated with diffractive bifocal IOL

Article

Bilateral implantation of the Acri.LISA 366D diffractive bifocal IOL is effective in ametropic and presbyopic eyes, according to findings published in the European Journal of Ophthalmology

Bilateral implantation of the Acri.LISA 366D diffractive bifocal IOL is effective in ametropic and presbyopic eyes, according to findings published in the European Journal of Ophthalmology.

A team led by Dr José F. Alfonso, Instituto Oftalmológico Fernández-Vega, Oviedo, Spain, studied 66 eyes in 33 consecutive patients. They were examined after refractive lens exchange (RLE) and implanted with the IOL. Eyes were split into myopic and hyperopic groups. The patient's monocular uncorrected distance visual acuity, best-corrected distance visual acuity (BCVA), uncorrected distance near visual acuity, and best distance-corrected near visual acuity (BCNVA) were measured preoperatively and at 6 months post-op.

The results showed that in the myopic group 2 eyes lost one line, 4 eyes gained 1 line and 6 eyes gained 2 lines. The hyperopic group 11 eyes lost 1 line, 8 eyes gained 1 line and 7 eyes gained 2 lines.

It was concluded that the use of Acri.LISA 366DD after RLE is an effective procedure for the treatment of presbyopia and ametropia.

Related Videos
Ana Neves, head of global marketing for ZEISS Meditec Ophthalmology
Fritz Hengerer, MD, PhD, Director, Eye Hospital at Bürgerhospital, Frankfurt, Germany
Dr Sheng Lim, professor of glaucoma studies at St Thomas' Hospital, London
Kasperi Kankare at the iCare booth at ESCRS
Scott D Barnes, MD, CMO of STAAR Surgical
Tomislav Bucalic, head of marketing at Geuder, and David Geuder, member of the executive board and CIO
Related Content
© 2023 MJH Life Sciences

All rights reserved.